Search research articles
Contact Us
Filters
Showing results (61-70 of 95) with videos related to
Page
of 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 9, 2004
Pharmacologically regulated regeneration of functional human pancreatic islets
Gary P Kobinger, Shaoping Deng, Jean-Pierre Louboutin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Suzanne George, Margaret von Mehren, Jonathan A Fletcher, et al.
Cell Reports. Medicine
|
October 18, 2023
Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing
Chuan Liu, Scott M Leighow, Kyle McIlroy, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2011
Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands
Changyu Zheng, Antonis Voutetakis, Benjamin Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies
Christine M Hartford, Apurva A Desai, Linda Janisch, et al.
Blood
|
January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
Wendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, et al.
Leukemia & Lymphoma
|
October 5, 2023
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports
Victor M Rivera-Francia, Virgilio E Failoc-Rojas, Robert Villacorta-Carranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Antonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Blood
|
September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Thomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 95) with videos related to
Sort By:
Page
of 10
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 9, 2004
Pharmacologically regulated regeneration of functional human pancreatic islets
Gary P Kobinger, Shaoping Deng, Jean-Pierre Louboutin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Suzanne George, Margaret von Mehren, Jonathan A Fletcher, et al.
Cell Reports. Medicine
|
October 18, 2023
Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing
Chuan Liu, Scott M Leighow, Kyle McIlroy, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2011
Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands
Changyu Zheng, Antonis Voutetakis, Benjamin Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies
Christine M Hartford, Apurva A Desai, Linda Janisch, et al.
Blood
|
January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
Wendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, et al.
Leukemia & Lymphoma
|
October 5, 2023
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports
Victor M Rivera-Francia, Virgilio E Failoc-Rojas, Robert Villacorta-Carranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Antonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Blood
|
September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Thomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Page
of 10